1. ALLA AKTIER
  2. NYHETER
  3. IDL DIAGNOSTICS

IDL Diagnostics

Nyheter IDL Diagnostics Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

The nomination committee's proposal for the board of IDL Diagnostics for the Annual General Meeting 2026

MARKN.

The nomination committee´s proposal for the board at the AGM is the re-election of Eva Nordström, Clas Runnberg, Per-Anders Abrahamsson and Max Pihlqvist. Agneta Tufvesson Alm has declined re-election to the board.

The Nomination Committee proposes the re-election of Max Pihlqvist as the Chairman of the Board.

Other proposals from the Nomination Committee will be provided in the notice for the Annual General Meeting.

IDL Diagnostics´ Nomination Committee consists of:
Jerker Swanstein (Chairman)
Jon Eiken
Didrik Hamilton

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@idldiagnostics.com

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye Sweden AB as company's Certified Adviser. For more information; www.idldiagnostics.com

Attachments

The nomination committee's proposal for the board of IDL Diagnostics for the Annual General Meeting 2026

Datum 2026-04-13, kl 10:00
Källa MFN
Bifogade filer
The nomination committee's proposal for the board of IDL Diagnostics for the Annual General Meeting 2026